A recent study published in the Journal of Biotechnology in 2021 presents a novel method for targeted gene integration in Chinese hamster ovary (CHO) cells using CRISPR/Cas9 technology. The research focuses on leveraging pseudo attP sites, which are naturally occurring genomic loci that resemble the attachment site of the phiC31 integrase system. By designing CRISPR/Cas9 guides to create double-strand breaks at these sites, the authors achieved precise integration of exogenous DNA without relying on viral vectors or random insertion. This approach enhances the stability and predictability of transgene expression, which is critical for biopharmaceutical production.
The study demonstrates successful targeting of multiple pseudo attP sites, with gene integration efficiencies comparable to traditional methods. The use of CRISPR/Cas9 provides a flexible and scalable platform for cell line engineering, potentially reducing the time and cost of developing stable CHO cell lines for recombinant protein manufacturing. The authors emphasize that this strategy minimizes off-target effects and maintains cell viability, making it a promising tool for industrial applications.
"This work represents a significant step toward rational cell engineering, combining the precision of CRISPR with the site-specific advantages of pseudo attP sites." – Study highlights.
Future directions include optimizing guide RNA design and exploring combinational targeting for multi-gene integration. The paper is a valuable resource for researchers in bioprocessing and synthetic biology.